Business Insider on MSN7d
The FDA is about to make weight-loss drugs a lot harder to getLots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Armed with this new safety and efficacy data from the current Study that has exceeded expectations, Lexaria intends to add a 5 th study arm - using DehydraTECH-tirzepatide in an oral capsule - to its ...
Lexaria intends to add a 5th study arm - using DehydraTECH-tirzepatide in an oral capsule - to its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm ...
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Hims & Hers has not offered compounded tirzepatide in the past ... means new leadership at the Department of Health and Human Services and the FDA, and Donald Trump has picked Ozempic-skeptic ...
Hosted on MSN1d
LEXX: IRB Approval Clears Way for GLP-1 Study #5LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Lilly seeks to protect interests in compounded drug case FDA affirms no shortage of tirzepatide drugs Compounded versions cheaper, often not covered by insurers Jan 2 (Reuters) - Eli Lilly (LLY.N ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback